Vitamin D deficiency in patients with active systemic lupus erythematosus
We investigated the effects of disease activity on bone metabolism in 36 patients with systemic lupus erythematosus (SLE). Changes in bone remodeling were not explained by corticosteroid use. A high prevalence of 25OHD deficiency in SLE patients indicates the need for vitamin D replacement, mainly during high disease activity periods.
We investigated the effects of SLE disease activity on bone metabolism, their relation to inflammatory cytokines and vitamin D levels.
We performed a cross-sectional analysis of 36 SLE patients classified according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in high activity (group I: 12 patients, mean age 29.6 years) or in minimal activity (group II: 24 patients, mean age 30.0 years), and compared them to normal controls (group III: 26 women, 32.8 years). Serum calcium, phosphorus, parathyroid and sex hormones, bone remodeling markers, interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), IL-1, tumor necrosis factor-α (TNF), 25-hydroxivitamin D (25OHD), and 1,25-dihydroxyvitamin D3 were measured, plus bone mineral density.
All cytokines were significantly higher in SLE groups; IL-6 could differentiate SLE patients from controls. In group I, 25OHD levels were lower (P < 0.05), which was related to the SLEDAI (R = -0.65, P < 0.001). In multiple regression analysis, the 25OHD level was associated with SLEDAI, osteocalcin and bone-specific alkaline phosphatase. The SLEDAI score was positively correlated with all measured cytokines and especially TNF (R = 0.75, P < 0.001).
SLE patients demonstrated changes in bone remodeling strongly related to disease activity. A high prevalence of 25OHD deficiency was observed in SLE patients, indicating the need for vitamin D replacement.
KeywordsBone markers Bone metabolism Cytokines Osteoporosis Systemic lupus erythematosus Vitamin D
- 5.Kalla AA, Fataar AB, Jessop SJ, Bewerunge L (1993) Loss of trabecular bone mineral density in systemic lupus erythematosus. S Afr Med J 36:1726–1734Google Scholar
- 12.Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T et al (1997) Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24:303–308PubMedGoogle Scholar
- 14.Saraiva GL, Cendoroglo MS, Ramos LR, Araujo LMQ, Vieira JGH, Kunii I, Hayashi LF, Correa MP, Marise Lazaretti-Castro M (2005) Influence of ultraviolet radiation on the production of 25 hydroxyvitamin D in the elderly population in the city of Sa˜o Paulo (23 o 34’S), Brazil. Osteoporos Int 16:1649–1654PubMedCrossRefGoogle Scholar
- 18.Vieira JG, Nishida SK, Kasamatsu T (1994) Development and clinical application of an immunofluorometric assay for intact parathyroid hormone. Brazilian J Med Biol Res 27:2379–2382Google Scholar
- 22.Romas E, Martin TJ (1997) Cytokines in the pathogenesis of osteoporosis. Osteop Int 7(Suppl 3):S47–S53Google Scholar
- 29.Hearth-Holmes M, Elder C, Wolf RE (1993) Bone Mineral Density (BMD) in Patients with Systemic Lupus Erythematosus (SLE). Arthritis Rheum 36:S229Google Scholar
- 36.Holick MF (1995) Vitamin D: photobiology, metabolism, and clinical applications. In: DeGroot LJ, Besser M, Burger HG et al (eds) Endocrinology, 3rd edn. WB Saunders Company, Philadelphia, pp 990–1014Google Scholar
- 37.Bouillon R, Okamura WH, Norman AW (1995) Structure-function relationships in the vitamin D endocrine system. Endocr Rev 20:22–45Google Scholar